Literature DB >> 31379197

Orthogonal analysis of dystrophin protein and mRNA as a surrogate outcome for drug development.

Kitipong Uaesoontrachoon1, Sadish Srinivassane1, Jordan Warford1, Kevork Mekhssian2, Hélène Montpetit2, Romain Beauvois2, Anahita Keyhani2, Yetrib Hathout3, Taishi Yamashita4, Youhei Satou4, Hironori Osaki4, Molly Praest1, Marina Moraca1, Maja Malbasic1, William Ross1, Alexandra MacKinnon1, Joyce Rowsell1, Amanda Mullen1, Mark Matyas1, Swati Mummidivarpu3, Kanneboyina Nagaraju1,3, Eric P Hoffman1,3.   

Abstract

Aim: Detection of drug-induced dystrophin in patient muscle biopsy is a surrogate outcome measure for Duchenne muscular dystrophy. We sought to establish and validate an orthogonal approach to measurement of dystrophin protein and RNA in muscle biopsies. Materials & methods: Validated methods were developed for dystrophin western blotting, mass spectrometry, immunostaining and reverse transcriptase PCR of biopsy mRNA using muscle biopsy standards.
Results: Both western blotting and mass spectrometry validated methods demonstrated good linearity, and acceptable precision and accuracy with a lower limit of quantitation at 1%. Immunostaining and reverse transcriptase PCR methods were shown to be reliable.
Conclusion: The described orthogonal approach is sufficient to support measures of dystrophin as a surrogate outcome in a clinical trial.

Entities:  

Keywords:  Duchenne muscular dystrophy; dystrophin; exon-skipping; muscle; oligonucleotide drug; phosphorodiamidate morpholino oligomer; surrogate biomarker

Mesh:

Substances:

Year:  2019        PMID: 31379197     DOI: 10.2217/bmm-2019-0242

Source DB:  PubMed          Journal:  Biomark Med        ISSN: 1752-0363            Impact factor:   2.851


  5 in total

1.  Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy.

Authors:  Vahid Farrokhi; Jason Walsh; Joe Palandra; Joanne Brodfuehrer; Teresa Caiazzo; Jane Owens; Michael Binks; Srividya Neelakantan; Florence Yong; Pinky Dua; Caroline Le Guiner; Hendrik Neubert
Journal:  Gene Ther       Date:  2021-11-05       Impact factor: 4.184

2.  Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.

Authors:  Paula R Clemens; Vamshi K Rao; Anne M Connolly; Amy D Harper; Jean K Mah; Edward C Smith; Craig M McDonald; Craig M Zaidman; Lauren P Morgenroth; Hironori Osaki; Youhei Satou; Taishi Yamashita; Eric P Hoffman
Journal:  JAMA Neurol       Date:  2020-08-01       Impact factor: 18.302

3.  A Novel Method for Detecting Duchenne Muscular Dystrophy in Blood Serum of mdx Mice.

Authors:  Nicole M Ralbovsky; Paromita Dey; Andrew Galfano; Bijan K Dey; Igor K Lednev
Journal:  Genes (Basel)       Date:  2022-07-27       Impact factor: 4.141

4.  Diagnosis of a model of Duchenne muscular dystrophy in blood serum of mdx mice using Raman hyperspectroscopy.

Authors:  Nicole M Ralbovsky; Paromita Dey; Andrew Galfano; Bijan K Dey; Igor K Lednev
Journal:  Sci Rep       Date:  2020-07-16       Impact factor: 4.379

Review 5.  Exon-Skipping in Duchenne Muscular Dystrophy.

Authors:  Shin'ichi Takeda; Paula R Clemens; Eric P Hoffman
Journal:  J Neuromuscul Dis       Date:  2021
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.